WO1999056749A1 - IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI) - Google Patents
IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI) Download PDFInfo
- Publication number
- WO1999056749A1 WO1999056749A1 PCT/AU1999/000321 AU9900321W WO9956749A1 WO 1999056749 A1 WO1999056749 A1 WO 1999056749A1 AU 9900321 W AU9900321 W AU 9900321W WO 9956749 A1 WO9956749 A1 WO 9956749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutically effective
- effective amount
- antibiotic
- ansamycin
- pylori
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to pharmaceutical compositions and therapeutic methods for the treatment and/or prevention of recurrence of gastrointestinal disorders associated with infection by Helicobacter pylori (H. pylori).
- Helicobacter pylori has been found to cause chronic histological gastritis and peptic ulcer disease, such as gastric and duodenal ulcer. It also appears to cause a condition called non-ulcer dyspepsia where Helicobacter pylori causes inflammation in the stomach which is histologically associated with indigestion and epigastric pain. Helicobacter pylori is also thought to have a role in the causation of stomach cancer and its eradication may be instrumental in causing cure of ulcer disease, a reversal of a proportion of patients with non-ulcer dyspepsia, and prevention of gastric cancer development in those who may be predisposed to it. Until recent times, H.
- H. pylori infections which are resistant to clarithromycin is increasing by from 2-5% per year. Resistance is developing faster in the countries where clarithromycin is being used frequently; in particular, USA and Europe. Hence, new methods for eradication of H. pylori are urgently required. In addition, salvage therapies for patients who have failed first time therapy are also unavailable and such treatments are becoming in demand as more and more patients undergo therapy and fail initial eradication attempts.
- the present inventor has found that the use of a novel combination antibiotic therapy not only results in high initial eradication rates of H. pylori but also can be used as a salvage therapy.
- Rifampicin is an antimycobacterial antibiotic used in the treatment of tuberculosis.
- the present invention provides a pharmaceutical composition for the treatment of gastrointestinal disorders associated with H. pylori infection including a first antibiotic which is an ansamycin, and at least a second antibiotic or antimicrobial agent, together with at least one pharmaceutically acceptable carrier, diluent, adjuvant or excipient.
- a first antibiotic which is an ansamycin
- a second antibiotic or antimicrobial agent together with at least one pharmaceutically acceptable carrier, diluent, adjuvant or excipient.
- the invention provides a method for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient requiring said treatment and/or prevention, which method comprises administering to said patient sequentially or simultaneously a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent.
- a method of treatment in accordance with the invention results in the eradication of H. pylori from the patient who is treated.
- the invention further provides the use of a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent for the manufacture of a medicament for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient.
- a first antibiotic which is an ansamycin
- a second antibiotic or antimicrobial agent for the manufacture of a medicament for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient.
- the invention still further provides a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent when used for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient.
- the ansamycin is selected from the group consisting of rifamycin, rifaximin, rifampicin, rifabutin and pharmaceutically acceptable salts thereof. More typically, the ansamycin is rifampicin or rifabutin. Preferably, the ansamycin is rifabutin.
- the pharmaceutical composition of the invention includes, in addition to the an ansamycin, one or more other antibiotics or antimicrobial agents.
- the pharmaceutical composition of the invention includes an ansamycin, typically rifabutin, and just one other antibiotic or antimicrobial agent.
- the pharmaceutical composition typically includes an ansamycin, typically rifabutin, and two different antibiotics or antimicrobial agents. In severe cases, or in cases where a resistant strain of H. pylori is encountered, three, four or even more antibiotics may be included together with the ansamycin.
- an ansamycin and a single other antibiotic or antimicrobial agent may be used, but more typically an ansamycin and two different other antibiotics or antimicrobial agents, or three, four or more, may be used.
- the active agents namely the ansamycin and the one or more other antibiotics or antimicrobial agents, may be administered simultaneously or sequentially, in any order.
- the pharmaceutical composition of the first embodiment may further include a proton pump inhibitor (PPI).
- a method of the second embodiment may further include the administration of a proton pump inhibitor.
- the inclusion of a PPI can help to enhance the eradication rate of H. pylori and can improve the patient's symptoms, since patients are often dyspeptic at the beginning of the treatment.
- the administration of the PPI in the method of the second embodiment may be separate from the administration of the ansamycm and other antibiotic(s) or antimicrobial agent(s), or the PPI may be co-administered with the ansamycin and/ or one or more other antibiotics or antimicrobial agents.
- Suitable PPIs include omeprazole, pantoprazole, lansoprazole and rabeprazole.
- the invention also provides the use of a therapeutically effective amount of an ansamycin, a therapeutically effective amount of at least one other antibiotic or antimicrobial agent, and a therapeutically effective amount of a proton pump inhibitor for the manufacture of a medicament for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient.
- the invention further provides a therapeutically effective amount of an ansamycin, a therapeutically effective amount of at least one other antibiotic or antimicrobial agent and a therapeutically effective amount of a proton pump inhibitor when used for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with H. pylori in a patient.
- the antibiotic(s) or antimicrobial agent(s) included in the pharmaceutical composition, method or use of the invention may be selected from the penicillins, bismuth compounds, tetracyclines, nitroimidazoles, quinolones, lincosamides, macrolides and cephalosporins.
- penicillins examples include penicillin G, penicillin V, pheneticillin, propicillin, methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, nafcillin, ampicillin, amoxycillin, bacampicillin, hetacillin, metampicillin, pivampicillin, talampicillin, carbenicillin, carfecillin, carindacillin, sulbenicillin, ticarcillin, azlocillin, mezlocillin, piperacillin, apalcillin, temocillin, mecillinam and pivmecillinam.
- bismuth compounds include bismuth subcitrate, bismuth aluminate, bismuth oxide, bismuth salicylate, bismuth sugballate, bismuth tannate, bismuth phosphate, bismuth tribromphenate, bismuth subcarbonate, bismuth subnitrate, and mixtures thereof.
- tetracyclines including tetracycline hydrochloride, oxytetracycline, doxycycline, methacycline, chlortetracycline, demeclocycline and minocycline.
- nitroimidazoles include metronidazole, tinidazole, nimorazole, ornidazole and orthanidazole.
- quinolones include ciprofloxacin, norfloxacin, enoxacin, lomefloxacin, pefloxacin, amifloxacin, fleroxacin, levofloxacin, nadifloxacin, rufloxacin, sparfloxacin, tosufloxacin and ofloxacin.
- lincosamides include lincomycin and clindamycin.
- macrolides include erythromycin, spiramycin, oleandomycin, triacetyloleandomycin, clarithromycin, roxithromycin, josamycin, kitsamycin, midecamycin, miocamycin, rokitamycin, dirithromycin,, rosarimycin, flurithromycin and azithromycin.
- cephalosporins examples include cephalexin, pivcephalexin, cephalothin, cephazolin, cefroxadine, cefadroxil, cefatrizine, cefaclor, cefprozil, cephradine, and second as well as third generation cephalosporins such as cephamandole, cefuroxime, cefuroxime axetil, cefonicid, ceforanide, cefotiam, cefotaxime, cefmenoxime, cefodizime, ceftizoxime, cefiximine, cefdinir, cefetamet pivoxil, cefpodoxime proxetil, ceftibuten, ceftazidime, ceftoperazone, cefpiramide, cefsoludin, cefepime, cefpirome and ceftriaxone, and related compounds such as oxycephalosporins including latamoxef, and cephamycins such
- rifabutin is used in combination with a penicillin as a first antibiotic, and a bismuth compound, as a second antimicrobial agent.
- a penicillin as a first antibiotic
- a bismuth compound as a second antimicrobial agent.
- An alternative second antimicrobial agent in this form of the invention is a tetracycline.
- rifabutin in previously untreated patients rifabutin can be used solely with clarithromycin, or rifabutin can be used in a triple therapy format with clarithromycin and a PPI such as pantoprazole. These all can be given in twice daily dosage or up to five times daily for more resistant strains. In the treatment of highly resistant strains where salvage therapy is required, three, four or even more of the antibiotics or antimicrobial agents exemplified above can be combined with rifabutin to affect a cure of Helicobacter pylori infection.
- pylori is a combination of rifabutin, clarithromycin and pantoprazole.
- Another preferred combination is a combination of rifabutin, amoxycillin and a PPI such as omeprazole, pantoprazole or lansoprazole.
- a further preferred combination is a combination of rifabutin, tetracycline and pantoprazole.
- rifabutin can be combined with bismuth subcitrate, amoxycillin, and a PPI such as pantoprazole or omeprazole.
- This combination has the added advantage that the dosage of each agent can be reduced, compared to clinically standard doses (with a reduction in the possibility of side effects as well as a reduction in cost) and the duration of treatment shortened, for example to 7 days.
- compositions of the invention include one or more pharmaceutically acceptable excipients, adjuvants, diluents or carriers which are generally known in the art.
- Pharmaceutical compositions of the invention or for administration in a method of the invention may be prepared by means known in the art for the preparation of pharmaceutical compositions including blending, grinding, homogenising, suspending, dissolving, emulsifying, dispersing and where appropriate, mixing of the active agents together with one or more excipients, diluents, carriers and adjuvants.
- the pharmaceutical composition may be in the form of tablets, lozenges, pills, troches, capsules, elixirs, powders, including lyophilised powders, solutions, granules, suspensions, emulsions, syrups and tinctures.
- Slow- release, or delay ed-release, forms may also be prepared, for example in the form of coated particles, multi-layer tablets or microgranules.
- Solid forms for oral administration may contain pharmaceutically acceptable binders, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents.
- Suitable binders include gum acacia, gelatin, corn starch, gum tragacanth, sodium alginate, carboxymethylcellulose or polyethylene glycol.
- Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine.
- Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar.
- Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate.
- Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring.
- Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten.
- Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite.
- Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc.
- Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
- Liquid forms for oral administration may contain, in addition to the active agents, a liquid carrier.
- suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
- Suspensions for oral administration may further include dispersing agents and/or suspending agents.
- Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, poly-vinyl-pyrrolidone, sodium alginate or cetyl alcohol.
- Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono- or di-oleate, - stearate or -laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like.
- Emulsions for oral administration may further include one or more emulsifying agents.
- Suitable emulsifying agents include dispersing agents as exemplified above or natural gums such as gum acacia or gum tragacanth.
- Dosages of the ansamycin and the other antibiotic(s) or antimicrobial agent(s) in the methods of the invention are in accordance with their generally known and safe dosage ranges.
- dosages for the antimicrobial agents are well known to medical practitioners, as are suitable dosages for rifabutin when it is administered for the treatment of tuberculosis or Mycobacterium avium complex infection.
- the typical daily dosage of rifabutin in a method of the invention is in the range of about 50mg to about 2000mg, more typically about 450mg .
- the typical daily dosage is in the range of from about 50mg to about 4000mg, more typically about 1500mg; for amoxycillin, the typical daily dosage is in the range of from about lOOmg to about 5000mg, more typically about 150omg; for bismuth the typical daily dosage is in the range of from about 50mg to about 2000mg, more typically about 300mg; and for pantoprazole the typical daily dosage is in the range of from about 20mg to about 500mg, more typically about 120mg.
- the agents may be administered once per day or more frequently, in divided doses. For example, rifabutin can be administered from twice daily up to five times daily. Treatment is typically continued until eradication of the H.
- pylori infection has been completed. Usually, the treatment is continued for from three days to 14 days, but can continue for up to 28 days. Dosages may be varied during the course of treatment, depending on the attending physician's assessment of the progress of the patient, or they may be maintained substantially the same throughout the treatment.
- the patient can be pretreated with known immunising agents for Helicobacter pylori and then treated with any selected combination of the rifabutin-containing combination therapies of the present invention.
- the Table presents the results of testing carried out on a number of patients using the epsilon test ("E-test" , AB Biodisc) which show that in all cases where there was infection by H. pylori which was resistant to one or both of metronidazole and clarithromycin, the infection was sensitive to rifabutin administration.
- the E-test is used as a graded antibiotic sensitivity detecting strip for examining resistance of H. pylori.
- Example 2 A male patient, 37 years old, who had been unsuccessfully treated previously for H. pylori infection using a combination of clarithromycin, amoxycillin and omeprazole was treated by administration of 4 times daily doses of rifabutin, pantoprazole and tetracycline in amounts of 600mg, 160mg and 2000mg per day respectively. After a period of 8 days on this treatment, the H. pylori infection in the patient had been eradicated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/673,631 US6489317B1 (en) | 1998-04-30 | 1999-04-30 | Method for eradication of Helicobacter pylori |
AU34006/99A AU762890B2 (en) | 1998-04-30 | 1999-04-30 | Improved method for eradication of Helicobacter Pylori |
EP99915381A EP1073436B1 (en) | 1998-04-30 | 1999-04-30 | Improved method for eradication of helicobacter pylori |
DE69933925T DE69933925T2 (en) | 1998-04-30 | 1999-04-30 | IMPROVED METHOD FOR ERADICATING HELICOBACTER PYLORI |
DK99915381T DK1073436T3 (en) | 1998-04-30 | 1999-04-30 | Improved method for eradication of Helicobacter pylori |
CA002330424A CA2330424C (en) | 1998-04-30 | 1999-04-30 | Improved method for eradication of helicobacter pylori |
CY20071100155T CY1106449T1 (en) | 1998-04-30 | 2007-02-05 | IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP3253A AUPP325398A0 (en) | 1998-04-30 | 1998-04-30 | Improved method for eradicating h. pylori |
AUPP3253 | 1998-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999056749A1 true WO1999056749A1 (en) | 1999-11-11 |
Family
ID=3807506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1999/000321 WO1999056749A1 (en) | 1998-04-30 | 1999-04-30 | IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI) |
Country Status (11)
Country | Link |
---|---|
US (1) | US6489317B1 (en) |
EP (1) | EP1073436B1 (en) |
AT (1) | ATE344664T1 (en) |
AU (1) | AUPP325398A0 (en) |
CA (1) | CA2330424C (en) |
CY (1) | CY1106449T1 (en) |
DE (1) | DE69933925T2 (en) |
DK (1) | DK1073436T3 (en) |
ES (1) | ES2276516T3 (en) |
PT (1) | PT1073436E (en) |
WO (1) | WO1999056749A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7993682B2 (en) | 2002-03-04 | 2011-08-09 | Thomas Julius Borody | Electrolyte purgative |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
US8785402B2 (en) * | 2009-07-31 | 2014-07-22 | Academia Sinica | Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions |
US9511080B2 (en) * | 2009-12-31 | 2016-12-06 | Okada Medical Services Pty Ltd | Okadaella gastrococcus and cancer |
DK2956149T3 (en) * | 2013-02-13 | 2019-09-09 | Redhill Biopharma Ltd | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI |
US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
CN117398360B (en) * | 2023-12-14 | 2024-03-15 | 山东齐都药业有限公司 | Compound preparation capsule for treating helicobacter pylori and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002039A1 (en) * | 1995-07-04 | 1997-01-23 | Pharmacia & Upjohn S.P.A. | Antibacterial synergistic composition comprising rifabutin |
WO1998043667A1 (en) * | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
-
1998
- 1998-04-30 AU AUPP3253A patent/AUPP325398A0/en not_active Abandoned
-
1999
- 1999-04-30 PT PT99915381T patent/PT1073436E/en unknown
- 1999-04-30 AT AT99915381T patent/ATE344664T1/en active
- 1999-04-30 CA CA002330424A patent/CA2330424C/en not_active Expired - Lifetime
- 1999-04-30 US US09/673,631 patent/US6489317B1/en not_active Expired - Lifetime
- 1999-04-30 WO PCT/AU1999/000321 patent/WO1999056749A1/en active IP Right Grant
- 1999-04-30 DE DE69933925T patent/DE69933925T2/en not_active Expired - Lifetime
- 1999-04-30 DK DK99915381T patent/DK1073436T3/en active
- 1999-04-30 EP EP99915381A patent/EP1073436B1/en not_active Expired - Lifetime
- 1999-04-30 ES ES99915381T patent/ES2276516T3/en not_active Expired - Lifetime
-
2007
- 2007-02-05 CY CY20071100155T patent/CY1106449T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997002039A1 (en) * | 1995-07-04 | 1997-01-23 | Pharmacia & Upjohn S.P.A. | Antibacterial synergistic composition comprising rifabutin |
WO1998043667A1 (en) * | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
Non-Patent Citations (7)
Title |
---|
DATABASE MEDLINE 1 January 1900 (1900-01-01), DE GIORGIO R, ET AL: "Rifaximin and Helicobacter Pylori Eradication", XP002946489, Database accession no. 1998219485 * |
GEVAUDAN M-J, BOLLET C, MALLET M-N: "MESURE DE L'ACTIVITE INTRA-MACROPHAGIQUE D'ASSOCIATIONS D'ANTIBIOTIQUES INTRA-MACROPHAGIC ACTIVITY OF ANTIBIOTICS COMBINATIONS AGAINST MYCOBACTERIUM MARINUM", PATHOLOGIE ET BIOLOGIE, L'EXPANSION SCIENTIFIQUE FRANCAISE, PARIS., FR, vol. 39, no. 05, 1 May 1991 (1991-05-01), FR, pages 436 - 441, XP000987253, ISSN: 0369-8114 * |
HOLTON J., ET AL.: "THE SUSCEPTIBILITY OF HELICOBACTER PYLORI TO THE RIFAMYCIN, REFAXIM.", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY., OXFORD UNIVERSITY PRESS, GB, vol. 35., no. 04., 1 April 1995 (1995-04-01), GB, pages 545 - 549., XP000600927, ISSN: 0305-7453, DOI: 10.1093/jac/35.4.545 * |
KUNIN C. M.: "ANTIMICROBIAL ACTIVITY OF RIFABUTIN.", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, vol. 22., no. SUPPL. 01., 1 April 1996 (1996-04-01), US, pages S03 - S14., XP000600925, ISSN: 1058-4838 * |
SHAFRAN S D, ET AL.: "A COMPARISON OF TWO REGIMENS FOR THE TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX BACTEREMIA IN AIDS: RIFABUTIN, ETHAMBUTOL, AND CLARITHROMYCIN VERSUS RIFAMPIN, ETHAMBUTOL, CLOFAZIMINE, AND CIPROFLOXACIN", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 335, no. 06, 8 August 1996 (1996-08-08), US, pages 377 - 383, XP000987186, ISSN: 0028-4793, DOI: 10.1056/NEJM199608083350602 * |
VAIRA D, ET AL.: "RIFAXIMIN SUSPENSION FOR THE ERADICATION OF HELICOBACTER PYLORI", CURRENT THERAPEUTIC RESEARCH., XX, XX, vol. 58, no. 05, 1 May 1997 (1997-05-01), XX, pages 300 - 308, XP000985836, DOI: 10.1016/S0011-393X(97)80027-6 * |
YAJKO D M, ET AL.: "IN VITRO ACTIVITIES OF RIFABUTIN, AZITHROMYCIN, CIPROFLOXACIN, CLARITHROMYCIN, CLOFAZIMINE, ETHAMBUTOL, AND AMIKACIN IN COMBINATIONS OF TWO, THREE, AND FOUR DRUGS AGAINST MYCOBACTERIUM AVIUM", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 40, no. 03, 1 March 1996 (1996-03-01), US, pages 743 - 749, XP000987080, ISSN: 0066-4804 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7993682B2 (en) | 2002-03-04 | 2011-08-09 | Thomas Julius Borody | Electrolyte purgative |
US8679549B2 (en) | 2002-03-04 | 2014-03-25 | Thomas Julius Borody | Electrolyte purgative |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
Also Published As
Publication number | Publication date |
---|---|
US6489317B1 (en) | 2002-12-03 |
EP1073436B1 (en) | 2006-11-08 |
ES2276516T3 (en) | 2007-06-16 |
DK1073436T3 (en) | 2007-03-19 |
CA2330424A1 (en) | 1999-11-11 |
AUPP325398A0 (en) | 1998-05-21 |
PT1073436E (en) | 2007-01-31 |
DE69933925D1 (en) | 2006-12-21 |
ATE344664T1 (en) | 2006-11-15 |
CY1106449T1 (en) | 2012-01-25 |
DE69933925T2 (en) | 2007-09-13 |
EP1073436A4 (en) | 2001-08-08 |
EP1073436A1 (en) | 2001-02-07 |
CA2330424C (en) | 2007-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11931463B2 (en) | All-in-one fixed-dose combination for treating Helicobacter pylori infection | |
EP0956857A2 (en) | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic | |
US20040048917A1 (en) | New use of compounds as antibacterial agents | |
RU2227033C2 (en) | Taurolidine and/or taurultam in treatment of infectious ulcer disease of infectious gastritis | |
EP1073436A1 (en) | IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI) | |
EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
US6426369B1 (en) | Oxethazaine as antimicrobial agent | |
AU3400699A (en) | Improved method for eradication of Helicobacter Pylori | |
Meijer et al. | Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers | |
US6162792A (en) | Use of spiramycin for treating gastrointestinal disorders caused by H. pylori | |
JP2000080031A (en) | Antimicrobial agent | |
O’Morain et al. | Helicobacter pylori and Duodenal Ulcer | |
JPH11246401A (en) | Therapeutic agent for helicobacter pylori infectious disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2330424 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 34006/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999915381 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09673631 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999915381 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 34006/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999915381 Country of ref document: EP |